Skip to main content

Research Division of Translational Medicine and Chemical Biology

The Division of Translational Medicine and Chemical Biology is focussed on understanding genome organisation and stability and develop novel technologies using latest genomics and chemical biology tools and preferentially using clinical material. We use our basic science insights as basis for translational medicine, where we develop novel treatments, and showing proof-of-concept in clinical trials in patients. Improving lives of patients is one of our prime objectives.

Research interests

The overall aim of the Division of Translational Medicine and Chemical Biology is to increase our understanding of genome organization, stability, DNA repair and disease metabolism. We develop and use novel techniques using high-throughput, genomics or chemical biology tools to study the basic science of genome maintenance and repair in clinical specimen from patients or cell cultures.

The Division also develops in-house single-cell and spatially resolved methods with the aim to quantify clinically relevant biomarkers and measure cellular drug responses. A strong focus is in the areas of DNA damage and repair, deubiquitinylation, chromatin structure and chromosome organization and understanding how these are involved in different diseases. Understanding perturbed metabolic pathways in disease is a key. We come up with new treatment strategies, which we validate in relevant clinical material.

We purify protein targets and characterize their biochemical and biophysical properties. This laying the grounds for our medicinal chemistry and pharmacology teams to identify and develop small molecules to target our target proteins of interest. We validate our small molecule approach in cells and tissues and carry out proof-of-concept experiments. Small molecules are further optimized and formulated into clinical drugs candidates, which are manufactured using Good Manufacturing Practice in laboratories certified by the Medical Products Agency and safety is further tested in Good Laboratory Practice certified laboratories in both small and large animal models. With regulatory approvals, we want to test our novel treatment concepts in proof-of-concept clinical trials for the benefit of patients and society.

Research groups

Magda Bienko Group
Our research focuses on understanding the interplay between genome organization and gene expression.

Nicola Crosetto Group
We develop new microscopy and sequencing methods to study genome fragility and tumor heterogeneity.


Visiting/Delivery address

Karolinska Institutet
SciLifeLab, alpha 5
Tomtebodavägen 23A
171 65 Stockholm


Postal Address

PO Box 1031
171 21 Solna